Department of Health and Human Services announced it was initiating a review process to consider removing a ban on the use of several of the most popular peptides
Mild headaches during adjustment are not a reason to stop therapy and usually don't indicate a safety issue
Current clinical consensus reflects the following: Research findings are preliminary and insufficient to guide treatment decisions No regulatory approval exists for using GLP-1s in addiction treatment Early signals do not outweigh the lack of long-term outcome data Instead, clinicians continue to recommend established, evidence-based approaches, including: Behavioral therapies tailored to substance use disorders Medication-assisted treatment when medically indicated Comprehensive psychosocial support and relapse-prevention planning Comprehensive assessment remains a cornerstone of safe and effective care
e) Ryan, D.H., Lingvay, I., Deanfield, J
(Journal of Investigative Dermatology, 2012) published landmark GHK-Cu research using microarray technology to map genome-wide expression changes
At Harley Skin & Laser Clinic, your health and wellbeing are paramount